Preventive effects of two PAF-antgonists, PMS 536 and PMS 549, on cyclosporin-induced LLC-PK1 oxidative injury

Journal of Lipid Mediators and Cell Signalling

Volumn 15, Issue 2, 1997, Pages 203-214

  Massicot, F ^a   Lamouri, A ^b   Martin, C ^a   Pham Huy, C ^a   Heymans, F ^b   Warnet, J M ^a   Godfroid, J J ^b   Claude, J R ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Laboratoire de Pharmacochimie   (France)

Author keywords

ATP; Cyclosporin A; glutathione; LLC PK1 cells; nephrotoxicity; PAF antagonist

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ALKALINE PHOSPHATASE; CYCLOSPORIN A; GLUTATHIONE; HYPOXANTHINE; MARKER; N ACETYL BETA GLUCOSAMINIDASE; PIPERAZINE DERIVATIVE; PMS 536; PMS 549; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG; URIC ACID;

ANIMAL CELL; ARTICLE; CELL LINE; CELL MEMBRANE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENERGY METABOLISM; KIDNEY TUBULE CELL; MEMBRANE STABILIZATION; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ACETYLGLUCOSAMINIDASE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ALKALINE PHOSPHATASE; ANIMALS; CYCLOSPORINE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; KIDNEY DISEASES; LLC-PK1 CELLS; OXIDATIVE STRESS; PIPERAZINES; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION INHIBITORS; SWINE;

EID: 0031053491     PISSN: 09297855     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-7855(96)00555-X     Document Type: Article

References (32)

1. Atkinson, D.E. (1968) The energy charge of adenylate pool as a regulatory parameter. Interaction with feedback modifiers. Biochemistry 7, 4030-4034.
2. Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
3. Braquet, P., Touqui, L., Shen, T.Y. and Vargaftig B.B. (1987) Perspectives in platelet-activating factor research. Pharmacol. Res. 39, 97-145.
4. Clostre, F. (1994) Pathophysiology of ischemia: an overview. In: F. Clostre and F.V. De Feudis (Eds.), Advances in Ginkgo Biloba Extract Research: Cardiovascular Effects of Ginkgo Biloba Extract (EGB 761), vol. 3, Elsevier, Paris, pp. 9-17.
5. Egido, J., Mendiluce, A., Mampaso, F., Gonzalez, E., et al. (1989) Protection against cyclosporin-induced nephropathy by PAF antagonists in rats. In: P. Braquet (Ed.), Ginkgolides: Chemistry Biology, Pharmacology and Clinical Perspectives, Vol. 2, J.R. Prous, Sci. Publishers, S.A., pp. 569.
6. English, J., Evans, A., Houghton, D.C., and Bennett, W.M. (1987) Cyclosporine-induced acute renal dysfunction in the rat: evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 44, 135-141.
7. Gomez-Chiarri, M., Egido, J., Gomez-Guerrero, C., et al. (1989) Production of PAF and cytokines by glomerular of rats with nephrotic syndrome: effect of the PAF receptor antagonist BN52021. In: P. Braquet (Ed.), Ginkgolides: Chemistry, Biology, Pharmacology and Clinical perspectives, Vol. 2, J.R. Prous, Sci. Publishers, S.A. pp. 581.
8. Griffith, O.W. (1980) Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal. Biochem. 106, 207-212.
9. Gunzler, W.A. and Flohe, L. (1985) Glutathione peroxidase. In: R.A. Greenwald (Ed.), CRC Handbook: Methods for Oxygen Radical Research, CRC Press, Boca Raton, FL, pp. 285-290.
10. Hanslik, T., Blanchet, D., Pirotzky, E., Guilmard, C., Seta, N. and Carbon, C. (1994) Effect of the platelet activating factor antagonist BN52021 in rabbits: role in gentamicin nephrotoxicity. Toxicol. Appl. Pharmacol. 128, 111-115.
11. Humes, H.O., Jackson, N.M., O'Conner, R.P., Hunt, D.A., and White, M.D. (1985) Pathogenic mechanisms of nephrotoxicity: insight into cyclosporine nephrotoxicity. Transplant. Proc. 17, 51.
12. Ito, S., Camussi, G., Tetta, C., Milgrom, F. and Andres, G. (1984) Hyperacute allograft rejection in the rabbit: the role of Platelet-Activating Factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets. Lab. Invest. 51, 148-161.
13. Jamil, K.M.A., Takano, T., Nakao, A. et al. (1992) Expression of Platelet Activating Factor receptor in renal tubular cell line (LLC-PK1). Biochem. Biophys. Res. Comm. 187, 767-772.
14. Koltai, M., Hosford, D. and Guinot, P. (1991) PAF - A review of its effects, antagonists and possible future clinical implications (II). Drugs 42, 174-204.
15. Lamouri, A., Heymans, F., Tavet, F. et al. (1993) Design and modeling of new PAF-antagonists. 1 - Synthesis and biological activity of 1,4-bis(3′,4′,5′-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbomoyl) oxy]methyl]-piperazines. J. Med. Chem. 36, 990-1000.
16. Langman, L.J. and Yatscoff, R.W. (1994) The effect of cyclosporine G (OG37-325), cyclosporine A and their metabolites on the release of vasoactive substances from primary renal cell lines. Transplant. Proc. 26, 3002-3005.
17. Leedle, R.A. and Aust, S.D. (1990) The effect of glutathione on the vitamin E requirement for inhibition of liver microsomal lipid peroxidation. Lipids 25, 241-245.
18. McCord, J.M. (1985) Oxygen-derived free radicals in post ischemic tissue injury. N. Engl. J. Med. 312, 159-163.
19. Mannervik, B. and Carlberg, I. (1985) Glutathione reductase. Methods Enzymol. 113, 484-490.
20. Mason, J. (1990) Renal side-effects of cyclosporin A. Br. J. Dermatol. 122 (Suppl. 36), 71-77.
21. Massicot, F., Pham Huy, C., Martin, C., Thevenin, M., Warnet, J.-M. and Claude, J.R. (1991) Inhibitory effects of a PAF-antagonist 48740 RP in cyclosporin-induced nephrotoxicity in the rat as assessed by renal glutathione metabolism parameters. Arch. Toxicol. 14 (Suppl.), 213-217.
22. Massicot, F., Thevenin, M., Martin, C., Warnet, J.-M., Dutertre-Catella, H. and Claude, J.R. (1994) Effects of cyclosporin on kidney glutathione metabolism and cytochrome P-450 in the rabbit: possible implication of eicosanoids. Drug Chem. Toxicol. 17, 449-462.
23. Massicot, F., Warnet, J.-M., Dutertre-Catella, H., Martin, C., Braquet, P. and Claude, J.R. (1994). Protection against cyclosporin-induced nephrotoxicity: 1. Effect of a PAF antagonist, BN50726. J. Lipid Mediators 9, 217-224.
24. Nalesnik, M.A., Lai, H.S., Murase, N. et al. (1990) The effect of FK506 and cyclosporine A on thé Lewis rat renal ischemia model. Transplant. Proc. 22 (Suppl. 1), 87-89.
25. Pavao dos Santos, O.F., Boim, M.A., Bregman, R. et al. (1989) Effect of Platelet-Activating Factor antagonist on cyclosporine nephrotoxicity. Transplantation 47, 592-595.
26. Pavao dos Santos, O.F., Boim, M.A., Barros, E. J.G., Pirotzky, E., Braquet, P. and Schor N. (1991) Effect of platelet-activating factor antagonist BN52063 on the nephrotoxicity of cisplatin. Lipids 26, 1324-1328.
27. Pham-Huy, C., Martin, C., Thevenin, M. et al. Determination of ATP, ADP, AMP and other nucleotides in tissues and cell culture by HPLC. Pharmacol. Toxicol. 73 (Suppl. II), 120 (Abstract).
28. Pirotzky, E., Colliez, Ph., Guilmard, C., Schaeverbeke, J. and Braquet, P. (1988) Cyclosporine-induced nephrotoxicity: preventive effect of a PAF-acether antagonist, BN52063. Transplant. Proc. 20 (Suppl. 3), 703-706.
29. Schlondorff, D. and Neuwirth, R. (1986) Platelet activating factor and the kidney. Am. J. Physiol. 251, F1-F11.
30. Sellak, H., Marquetty, C., and Pasquier, C. (1994) Endothelial-cell protection against oxygen free-radical injury by Ginkgo biloba extract. In: F. Clostre and F.V. De Feudis (Eds.), Advances in Ginkgo Biloba Extract Research. Cardiovascular Effects of Ginkgo Biloba Extract (EGB 761), Vol. 3., Elsevier, Paris, pp. 69-78.
31. Walker, R.J., Lazzaro, V.A., Duggin, G.G., Horvath, J.S. and Tiller, D.J. (1990) Evidence that alterations in renal metabolism and lipid peroxidation may contribute to cyclosporin nephrotoxicity. Transplantation 50, 487-492.
32. Walker, R.J. and Duggin, G.G. (1992) Cellular mechanisms of drug nephrotoxicity. Drug Nephrotox. 106, 3571-3595.